Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul;21(4):528-39.
doi: 10.1097/EDE.0b013e3181df1b69.

Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization

Sengwee Toh  1 , Sonia Hernández-Díaz, Roger Logan, James M Robins, Miguel A Hernán
Affiliations
Randomized Controlled Trial

Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization

Sengwee Toh et al. Epidemiology. 2010 Jul.

Abstract

The intention-to-treat (ITT) analysis provides a valid test of the null hypothesis and naturally results in both absolute and relative measures of risk. However, this analytic approach may miss the occurrence of serious adverse effects that would have been detected under full adherence to the assigned treatment. Inverse probability weighting of marginal structural models has been used to adjust for nonadherence, but most studies have provided only relative measures of risk. In this study, we used inverse probability weighting to estimate both absolute and relative measures of risk of invasive breast cancer under full adherence to the assigned treatment in the Women's Health Initiative estrogen-plus-progestin trial. In contrast to an ITT hazard ratio (HR) of 1.25 (95% confidence interval [CI] = 1.01 to 1.54), the HR for 8-year continuous estrogen-plus-progestin use versus no use was 1.68 (1.24 to 2.28). The estimated risk difference (cases/100 women) at year 8 was 0.83 (-0.03 to 1.69) in the ITT analysis, compared with 1.44 (0.52 to 2.37) in the adherence-adjusted analysis. Results were robust across various dose-response models. We also compared the dynamic treatment regimen "take hormone therapy until certain adverse events become apparent, then stop taking hormone therapy" with no use (HR = 1.64; 95% CI = 1.24 to 2.18). The methods described here are also applicable to observational studies with time-varying treatments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion of women free of invasive breast cancer--intention-to-treat analysis, Women’s Health Initiative estrogen-plus-progestin randomized trial. Kaplan-Meier (unadjusted) curves on top panel; standardized (adjusted) curves on bottom panel.
Figure 2
Figure 2
Estimated proportion of women free of invasive breast cancer under continuous adherence to the assigned treatment, Women’s Health Initiative estrogen-plus-progestin randomized trial
See this image and copyright information in PMC

References

    1. Robins JM. Correction for non-compliance in equivalence trials. Stat Med. 1998;17(3):269–302. discussion 387-9. - PubMed
    1. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550–60. - PubMed
    1. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11(5):561–70. - PubMed
    1. Toh S, Hernán MA. Causal inference from longitudinal studies with baseline randomization. Int J Biostat. 2008;4(1):Article 22. Available at: http://www.bepress.com/ijb/vol4/iss1/22. - PMC - PubMed
    1. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779–88. - PubMed

Publication types

MeSH terms